

## Highlights of This Issue 1121

## SPECIAL FEATURES

## CCR Translations

- 1123** Combining Molecularly Targeted Agents: Is More Always Better?



Raghav Sundar, Nicola Valeri, Kevin J. Harrington, and Timothy A. Yap

See related article, p. 1177

## CCR New Strategies

- 1126** New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies

Rachel C. Jankowitz, Steffi Oesterreich, Adrian V. Lee, and Nancy E. Davidson

## Molecular Pathways

- 1132** Molecular Pathways: The Necrosome—A Target for Cancer Therapy

Lena Seifert and George Miller

## Review

- 1137** Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients



Razelle Kurzrock and David J. Stewart

## CLINICAL TRIAL BRIEF REPORT

- 1149** Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma



Steven E. Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, and Susan O'Brien

## CANCER THERAPY: CLINICAL

- 1156** Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial



Chun-Meng Wang, Zhi-Qiang Wu, Yao Wang, Ye-Lei Guo, Han-Ren Dai, Xiao-Hui Wang, Xiang Li, Ya-Jing Zhang, Wen-Ying Zhang, Mei-Xia Chen, Yan Zhang, Kai-Chao Feng, Yang Liu, Su-Xia Li, Qing-Ming Yang, and Wei-Dong Han

- 1167** Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Ranjana H. Advani, Daniel Lebovic, Andy Chen, Mark Brunvand, Andre Goy, Julie E. Chang, Ephraim Hochberg, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Priya Agarwal, Randall C. Dere, Hsin-Ju Hsieh, Surai Jones, Yu-Way Chu, and Bruce D. Cheson

- 1177** A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors



Emiliano Calvo, Jean-Charles Soria, Wen Wee Ma, Tao Wang, Rastilav Bahleda, Anthony W. Tolcher, Diana Gernhardt, Joseph O'Connell, Robert Millham, Nagdeep Giri, Michael J. Wick, Alex A. Adjei, and Manuel Hidalgo

See related commentary, p. 1123

- 1186** Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies

Kevin Kelly, Alex Mejia, Avvaru N. Suhasini, An-Ping Lin, John Kuhn, Anand B. Karnad, Steven Weitman, and Ricardo C.T. Aguiar

- 1193** Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer



Marie-Kristin von Wahlde, Kirsten M. Timms, Anees Chagpar, Vikram B. Wali, Tingting Jiang, Veerle Bossuyt, Ozlen Saglam, Julia Reid, Alexander Gutin, Chris Neff, Jerry S. Lanchbury, Christos Hatzis, Erin Hofstatter, and Lajos Pusztai

# Table of Contents

## PERSONALIZED MEDICINE AND IMAGING

- 1200** **A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer**  
Manuela Salvucci, Maximilian L. Würstle, Clare Morgan, Sarah Curry, Mattia Cremona, Andreas U. Lindner, Orna Bacon, Alexa J. Resler, Áine C. Murphy, Robert O'Byrne, Lorna Flanagan, Sonali Dasgupta, Nadege Rice, Camilla Pilati, Elisabeth Zink, Lisa M. Schöller, Sinead Toomey, Mark Lawler, Patrick G. Johnston, Richard Wilson, Sophie Camilleri-Broët, Manuel Salto-Tellez, Deborah A. McNamara, Elaine W. Kay, Pierre Laurent-Puig, Sandra Van Schaeysbroeck, Bryan T. Hennessy, Daniel B. Longley, Markus Rehm, and Jochen H.M. Prehn
- 1213** **A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non-Small Cell Lung Cancer**  
Ingo Mecklenburg, Wulf Sielen, Severin Schmid, Bernward Passlick, and Peter Kufner
- 1220** **Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer**  
Julie George, Motonobu Saito, Koji Tsuta, Reika Iwakawa, Kouya Shiraishi, Andreas H. Scheel, Shinsuke Uchida, Shun-ichi Watanabe, Ryo Nishikawa, Masayuki Noguchi, Martin Peifer, Se Jin Jang, Iver Petersen, Reinhard Büttner, Curtis C. Harris, Jun Yokota, Roman K. Thomas, and Takashi Kohno
- 1227** **Targeted Sequencing Reveals Low-Frequency Variants in *EPHA* Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy**  
María Apellániz-Ruiz, Héctor Tejero, Lucía Inglada-Pérez, Lara Sánchez-Barroso, Gerardo Gutiérrez-Gutiérrez, Isabel Calvo, Beatriz Castelo, Andrés Redondo, Jesús García-Donás, Nuria Romero-Laorden, María Sereno, María Merino, María Currás-Freixes, Cristina Montero-Conde, Veronika Mancikova, Elisabeth Ávall-Lundqvist, Henrik Green, Fátima Al-Shahrour, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona
- 1236** ***BRCA1*-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency**  
Esther H. Lips, Rashmie D. Debipersad, Caroline E. Scheerman, Lennart Mulder, Gabe S. Sonke, Lizet E. van der Kolk, Jelle Wesseling, Frans B.L. Hogervorst, and Petra M. Nederlof

## CANCER THERAPY: PRECLINICAL

- 1242** **Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy**  
Naz Chaudary, Melania Pintilie, Salomeh Jelveh, Patricia Lindsay, Richard P. Hill, and Michael Milosevic
- 1250** **Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism**  
Anda-Alexandra Calinescu, Viveka Nand Yadav, Erica Carballo, Padma Kadiyala, Dustin Tran, Daniel B. Zmler, Robert Doherty, Maithreyi Srikanth, Pedro Ricardo Lowenstein, and Maria Graciela Castro
- 1263** **Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics**  
Joyce F. Liu, Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Elena Ivanova, Wei Huang, Ioannis K. Zervantonakis, Laura M. Selfors, Yiping Shen, Colin C. Pritchard, Mei Zheng, Vilmos Adleff, Eniko Papp, Huiying Piao, Marian Novak, Susan Fotheringham, Gerburg M. Wulf, Jessie English, Paul T. Kirschmeier, Victor E. Velculescu, Cloud Paweletz, Gordon B. Mills, David M. Livingston, Joan S. Brugge, Ursula A. Matulonis, and Ronny Drapkin
- 1274** **Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative**  
Tine Cuppens, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel García-Jimenez, Koen Van de Vijver, Roy P.M. Kruitwagen, Mariël Brinkhuis, Michal Zikan, Pavel Dundr, Jutta Huvila, Olli Carpén, Johannes Haybaeck, Farid Moinfar, Helga B. Salvesen, Maciej Stukan, Carole Mestdagh, Ronald P. Zweemer, Leonardus F. Massuger, Michael R. Mallmann, Eva Wardelmann, Miriam Mints, Godelieve Verbist, Debby Thomas, Ellen Gommé, Els Hermans, Philippe Moerman, Tjalling Bosse, and Frédéric Amant
- 1286** **PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models**  
Fan Lin, Mark C. de Gooijer, Diana Hanekamp, Gayathri Chandrasekaran, Levi C.M. Buil, Nishita Thota, Rolf W. Sparidans, Jos H. Beijnen, Tom Würdinger, and Olaf van Tellingen

# Table of Contents

## BIOLOGY OF HUMAN TUMORS

- 1299** Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors  
Hye-Young Min, Su-Chan Lee, Jong Kyu Woo, Hyun Jin Jung, Kwan Hee Park, Hae Min Jeong, Seung Yeob Hyun, Jaebeom Cho, Woonin Lee, Ji Eun Park, So Jung Kwon, Hyo-Jong Lee, Xiao Ni, Young Kee Shin, Faye M. Johnson, Madeleine Duvic, and Ho-Young Lee
- 1312** Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer  
Kunitoshi Shigeyasu, Yoshinaga Okugawa, Shusuke Toden, C. Richard Boland, and Ajay Goel
- 1323** Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis  
Martin Pichler, Verena Stiegelbauer, Petra Vychytilova-Faltejskova, Cristina Ivan, Hui Ling, Elke Winter, Xinna Zhang, Matthew Goblirsch, Annika Wulf-Goldenberg, Masahisa Ohtsuka, Johannes Haybaeck, Marek Svoboda, Yoshinaga Okugawa, Armin Gerger, Gerald Hoefler, Ajay Goel, Ondrej Slaby, and George Adrian Calin

- 1334** Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in *RET*<sup>M918T</sup> Tumors  
Veronika Mancikova, Cristina Montero-Conde, Javier Perales-Paton, Agustin Fernandez, María Santacana, Karolina Jodkowska, Lucia Inglada-Pérez, Esmeralda Castelblanco, Salud Borrego, Mario Encinas, Xavier Matias-Guiu, Mario Fraga, and Mercedes Robledo
- 1346** Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer  
Santosh Gupta, Jing Li, Gabor Kemeny, Rhonda L. Bitting, Joshua Beaver, Jason A. Somarelli, Kathryn E. Ware, Simon Gregory, and Andrew J. Armstrong

## CORRECTIONS

- 1358** Correction: PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
- 1359** Correction: Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy
- 1361** Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases *In Vitro* and *In Vivo*




AC icon indicates Author Choice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# Table of Contents

## ABOUT THE COVER

The cover shows a micrograph of the intracranial subventricular zone of an 11-day-old mouse that was injected 10 days prior with DNA encoding NRAS and SV40-LgT to generate glioblastoma. Cells expressing the chemokine CXCL12 are shown in magenta. Some of these cells have taken up the DNA, as evidenced by expression of SV40-LgT (green). For details see the article by Calinescu and colleagues on page 1250 of this issue.



# Clinical Cancer Research

**23 (5)**

*Clin Cancer Res* 2017;23:1121-1361.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/23/5>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/5>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.